var data={"title":"Reducing bleeding and minimizing blood transfusion during surgery","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Reducing bleeding and minimizing blood transfusion during surgery</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/contributors\" class=\"contributor contributor_credentials\">Thomas J Graetz, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/contributors\" class=\"contributor contributor_credentials\">Gregory Nuttall, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/contributors\" class=\"contributor contributor_credentials\">Steven Kleinman, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/contributors\" class=\"contributor contributor_credentials\">Nancy A Nussmeier, MD, FAHA</a></dd><dd><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 14, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H10487453\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This topic will review perioperative strategies to avoid or minimize transfusion of blood products during surgery and other interventional procedures. General principles guiding intraoperative transfusion decisions as well as indications and risks associated with transfusion of specific blood components in that setting are discussed separately. (See <a href=\"topic.htm?path=intraoperative-transfusion-of-blood-products-in-adults\" class=\"medical medical_review\">&quot;Intraoperative transfusion of blood products in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2373181178\"><span class=\"h1\">PREOPERATIVE STRATEGIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The preanesthetic consultation provides an opportunity to assess and minimize risks for bleeding and transfusion. Certain medications, diseases, and surgical procedures are associated with increased risks for transfusion [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/1\" class=\"abstract_t\">1</a>]. It may be appropriate to postpone an elective procedure if consultation with the surgeon <span class=\"nowrap\">and/or</span> hematologist determines that the benefit of optimizing hemostasis or hemoglobin level outweighs the risks of postponing the surgery. (See <a href=\"topic.htm?path=preoperative-assessment-of-hemostasis#H17\" class=\"medical medical_review\">&quot;Preoperative assessment of hemostasis&quot;, section on 'Medical and hematologic consultations'</a>.)</p><p class=\"headingAnchor\" id=\"H2354604631\"><span class=\"h2\">Selective laboratory testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A baseline hemoglobin measurement is suggested for patients &ge;65 years old who are undergoing major elective surgery and for any patient undergoing a procedure expected to result in significant blood loss. In contrast, hemoglobin measurement is unnecessary for healthy adults undergoing minor surgery unless the history suggests anemia. (See <a href=\"topic.htm?path=preoperative-medical-evaluation-of-the-adult-healthy-patient#H13\" class=\"medical medical_review\">&quot;Preoperative medical evaluation of the adult healthy patient&quot;, section on 'Complete blood count'</a>.)</p><p>No additional laboratory testing is required unless a bleeding disorder is suspected. This practice is consistent with the American Society of Anesthesiologists (ASA) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/2\" class=\"abstract_t\">2</a>], the British Committee for Standards in Hematology (BCSH) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/3\" class=\"abstract_t\">3</a>], and the European Society of Anaesthesia (ESA) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/4\" class=\"abstract_t\">4</a>].</p><p>If the patient or family history or the physical examination suggests the presence of a bleeding disorder, appropriate screening tests should be performed, including prothrombin time (PT) with international normalized ratio (INR), activated partial thromboplastin time (aPTT), and platelet count. A hematology consultation and additional testing are typically necessary to establish a diagnosis and treatment plan. In some cases such as those with significant prior bleeding (eg, drop in hemoglobin level, need for transfusions) it may be appropriate to pursue consultation even when screening tests are normal. (See <a href=\"topic.htm?path=preoperative-assessment-of-hemostasis#H6\" class=\"medical medical_review\">&quot;Preoperative assessment of hemostasis&quot;, section on 'Laboratory testing'</a> and <a href=\"topic.htm?path=preoperative-assessment-of-hemostasis#H17\" class=\"medical medical_review\">&quot;Preoperative assessment of hemostasis&quot;, section on 'Medical and hematologic consultations'</a>.)</p><p>When screening is indicated, it should be done early enough to allow time for diagnosis and treatment of the causes of anemia or hemostatic abnormalities. Elective surgery may be delayed to allow time to identify and potentially correct abnormalities [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult#H1539385\" class=\"medical medical_review\">&quot;Indications and hemoglobin thresholds for red blood cell transfusion in the adult&quot;, section on 'Hospital-wide oversight programs'</a>.)</p><p>Typing and crossmatching considerations to ensure availability of appropriate blood products for cases with large expected blood loss are discussed separately. (See <a href=\"topic.htm?path=intraoperative-transfusion-of-blood-products-in-adults#H4216519216\" class=\"medical medical_review\">&quot;Intraoperative transfusion of blood products in adults&quot;, section on 'Preparations for large expected blood losses'</a>.)</p><p class=\"headingAnchor\" id=\"H2290460988\"><span class=\"h2\">Management of medications affecting hemostasis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients undergoing surgery are taking medications intended to impair normal hemostasis (eg, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> or other anticoagulants, <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or other antiplatelet agents). In some cases, medications prescribed for other indications may alter hemostasis (eg, nonsteroidal antiinflammatory drugs [NSAIDs], herbal medications).</p><p>Appropriate perioperative management of a patient taking a specific medication depends upon the indication for which the agent was prescribed and the planned surgical procedure. Management is discussed in separate topics:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anticoagulants. (See <a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants\" class=\"medical medical_review\">&quot;Perioperative management of patients receiving anticoagulants&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Importantly, not all individuals require reversal of the anticoagulant, especially if thrombotic risk from an underlying condition is high and bleeding risk of the surgery is low. In addition, some of these agents including heparin and direct oral anticoagulants (DOACs) have short half-lives and discontinuation at a specified interval prior to the procedure is sufficient to eliminate their anticoagulant effect. If it is determined that the patient requires anticoagulant reversal, the following strategies are used:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">Warfarin</a> or other vitamin K antagonist (<a href=\"image.htm?imageKey=HEME%2F79151\" class=\"graphic graphic_table graphicRef79151 \">table 1</a> and <a href=\"image.htm?imageKey=EM%2F89478\" class=\"graphic graphic_table graphicRef89478 \">table 2</a>). (See <a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants\" class=\"medical medical_review\">&quot;Perioperative management of patients receiving anticoagulants&quot;</a> and <a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr\" class=\"medical medical_review\">&quot;Management of warfarin-associated bleeding or supratherapeutic INR&quot;</a>.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>DOACs (direct oral thrombin inhibitor <a href=\"topic.htm?path=dabigatran-drug-information\" class=\"drug drug_general\">dabigatran</a> and direct factor Xa inhibitors) (<a href=\"image.htm?imageKey=HEME%2F96230\" class=\"graphic graphic_table graphicRef96230 \">table 3</a> and <a href=\"image.htm?imageKey=HEME%2F112299\" class=\"graphic graphic_table graphicRef112299 \">table 4</a>). (See <a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants\" class=\"medical medical_review\">&quot;Perioperative management of patients receiving anticoagulants&quot;</a> and <a href=\"topic.htm?path=management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants\" class=\"medical medical_review\">&quot;Management of bleeding in patients receiving direct oral anticoagulants&quot;</a>.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Heparin. (See <a href=\"topic.htm?path=heparin-and-lmw-heparin-dosing-and-adverse-effects#H81746\" class=\"medical medical_review\">&quot;Heparin and LMW heparin: Dosing and adverse effects&quot;, section on 'Reversal'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a>. (See <a href=\"topic.htm?path=fondaparinux-dosing-and-adverse-effects#H831144\" class=\"medical medical_review\">&quot;Fondaparinux: Dosing and adverse effects&quot;, section on 'Management and prevention of bleeding'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiplatelet agents (eg, <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, other antiplatelet agents, nonsteroidal antiinflammatory agents). (See <a href=\"topic.htm?path=perioperative-medication-management#H25\" class=\"medical medical_review\">&quot;Perioperative medication management&quot;, section on 'Medications affecting hemostasis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Herbal medications that affect hemostasis (eg, ginkgo biloba, garlic). (See <a href=\"topic.htm?path=perioperative-medication-management#H46\" class=\"medical medical_review\">&quot;Perioperative medication management&quot;, section on 'Herbal medications'</a>.) &#160;</p><p/><p class=\"headingAnchor\" id=\"H1710529857\"><span class=\"h2\">Correction of anemia or thrombocytopenia</span></p><p class=\"headingAnchor\" id=\"H2062982004\"><span class=\"h3\">Correction of anemia in selected patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Preoperative anemia is strongly associated with increased risk of transfusion in surgical patients. A hemoglobin concentration &lt;13.5 <span class=\"nowrap\">g/dL</span> (&lt;135 <span class=\"nowrap\">g/L)</span> or a hematocrit (HCT) &lt;41.0 percent represents anemia in men, while a value &lt;12.0 <span class=\"nowrap\">g/dL</span> (&lt;120 <span class=\"nowrap\">g/L)</span> or &lt;36.0 percent represents anemia in women. Depending on the cause and degree of anemia and the urgency of the procedure, correction could potentially be accomplished prior to elective surgery [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/1,6,7\" class=\"abstract_t\">1,6,7</a>]. (See <a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult#H1539385\" class=\"medical medical_review\">&quot;Indications and hemoglobin thresholds for red blood cell transfusion in the adult&quot;, section on 'Hospital-wide oversight programs'</a>.)</p><p>In selected patients, erythropoietin (EPO) <span class=\"nowrap\">and/or</span> iron may be administered before elective or semi-elective surgery to correct anemia and avoid transfusion [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/1,6-10\" class=\"abstract_t\">1,6-10</a>]. It is prudent to allow sufficient time for correction of iron deficiency before surgery (typically two to four weeks for partial correction and six to eight weeks for full correction) (see <a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults#H9250324\" class=\"medical medical_review\">&quot;Treatment of iron deficiency anemia in adults&quot;, section on 'Response to iron supplementation'</a>). Examples with specific treatments include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic kidney disease, with or without hemodialysis. (See <a href=\"topic.htm?path=treatment-of-anemia-in-nondialysis-chronic-kidney-disease#H429553047\" class=\"medical medical_review\">&quot;Treatment of anemia in nondialysis chronic kidney disease&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=treatment-of-anemia-in-hemodialysis-patients#H3994049381\" class=\"medical medical_review\">&quot;Treatment of anemia in hemodialysis patients&quot;, section on 'Treatment'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Iron deficiency or iron deficiency anemia. In one study in 65 patients with hemoglobin concentration &lt;13 <span class=\"nowrap\">g/dL,</span> intravenous (IV) EPO was administered together with IV iron (<a href=\"topic.htm?path=ferric-carboxymaltose-drug-information\" class=\"drug drug_general\">ferric carboxymaltose</a>) 21 days before elective major orthopedic surgery, followed by an additional EPO injection 14 days before surgery [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/10\" class=\"abstract_t\">10</a>]. If hemoglobin concentration remained &lt;13 <span class=\"nowrap\">g/dL</span> after this initial therapy, additional EPO injections were administered. This resulted in an increase in hemoglobin level but no difference in the rate of transfusion. (See <a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">&quot;Treatment of iron deficiency anemia in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cancer-associated anemia associated with inflammation or due to bleeding. (See <a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer\" class=\"medical medical_review\">&quot;Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Religious beliefs that preclude acceptance of transfusion. (See <a href=\"topic.htm?path=the-approach-to-the-patient-who-refuses-blood-transfusion#H444540220\" class=\"medical medical_review\">&quot;The approach to the patient who refuses blood transfusion&quot;, section on 'Erythropoiesis-stimulating agents (ESAs) and intravenous iron'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain hereditary anemias such as sickle cell disease, treated with preoperative transfusion to reduce the percentage of sickle hemoglobin. (See <a href=\"topic.htm?path=red-blood-cell-transfusion-in-sickle-cell-disease#H8398540\" class=\"medical medical_review\">&quot;Red blood cell transfusion in sickle cell disease&quot;, section on 'Prophylactic preoperative transfusion'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3787518421\"><span class=\"h3\">Treatment of thrombocytopenia for selected procedures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Depending on the type and urgency of the surgical procedure and the cause and degree of thrombocytopenia, therapy to increase the platelet count may be given prior to surgery.<strong> </strong></p><p>For emergent major surgery, platelets are transfused if the count is <span class=\"nowrap\">&lt;50,000/microL</span>. A higher transfusion threshold is used in selected cases (eg, <span class=\"nowrap\">&lt;100,000/microL</span> for neurosurgery). However, platelet transfusion is usually unnecessary for a minor invasive procedure (eg, placement of a central venous catheter) unless the count is <span class=\"nowrap\">&lt;20,000/microL</span> [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/11\" class=\"abstract_t\">11</a>]. Suggested platelet count thresholds for common invasive procedures are discussed separately. (See <a href=\"topic.htm?path=clinical-and-laboratory-aspects-of-platelet-transfusion-therapy#H558384448\" class=\"medical medical_review\">&quot;Clinical and laboratory aspects of platelet transfusion therapy&quot;, section on 'Preparation for an invasive procedure'</a>.)</p><p>For some elective procedures in patients with immune thrombocytopenia (ITP), properly-timed glucocorticoids <span class=\"nowrap\">and/or</span> IV <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG) can be used to raise the platelet count before surgery. The table shows the expected time to first response for various ITP treatments (<a href=\"image.htm?imageKey=HEME%2F87698\" class=\"graphic graphic_table graphicRef87698 \">table 5</a>). We generally use the agent that has previously been effective for the individual patient. (See <a href=\"topic.htm?path=immune-thrombocytopenia-itp-in-adults-initial-treatment-and-prognosis#H15659153\" class=\"medical medical_review\">&quot;Immune thrombocytopenia (ITP) in adults: Initial treatment and prognosis&quot;, section on 'Surgery/invasive procedures'</a>.). </p><p class=\"headingAnchor\" id=\"H988137511\"><span class=\"h2\">Treatment of vitamin K deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vitamin K deficiency may develop in individuals with reduced oral intake or decreased absorption due to conditions such as cystic fibrosis, biliary atresia, sclerosing cholangitis, cholestasis, or intestinal diseases with malabsorption. Significant vitamin K deficiency will prolong the prothrombin time (PT). Vitamin K deficiency can be treated with vitamin K, which may take one or more days to be effective, or with an unactivated prothrombin complex concentrate (PCC) if needed for emergent surgery with a significant bleeding risk. (See <a href=\"topic.htm?path=overview-of-vitamin-k#H10\" class=\"medical medical_review\">&quot;Overview of vitamin K&quot;, section on 'Deficiency'</a>.) </p><p class=\"headingAnchor\" id=\"H2401243333\"><span class=\"h2\">Management of anemia and hemostasis in renal insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with end-stage renal disease (ESRD) typically have chronic anemia. Management may include iron <span class=\"nowrap\">and/or</span> erythropoietin. We generally do not transfuse stable ESRD patients with hemoglobin &gt;7 <span class=\"nowrap\">g/dL</span> in the absence of a specific indication. In particular, transfusion is avoided in any patient on a transplant waiting list if possible, because transfusion-induced sensitization may increase antibody levels and reduce the likelihood of eventual successful renal transplantation [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/12\" class=\"abstract_t\">12</a>]. These issues are discussed in detail separately. (See <a href=\"topic.htm?path=medical-management-of-the-dialysis-patient-undergoing-surgery#H5\" class=\"medical medical_review\">&quot;Medical management of the dialysis patient undergoing surgery&quot;, section on 'Anemia status'</a>.)</p><p>Although not all uremic patients have a bleeding diathesis, many have an increased tendency to bleed during surgery due to platelet inhibition by uremia, dysfunctional von Willebrand factor (VWF), residual heparin used for dialysis, or increased production of nitric oxide (a vasodilator and platelet function inhibitor) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/13\" class=\"abstract_t\">13</a>]. Management of a bleeding diathesis in patients with ESRD is discussed separately. (See <a href=\"topic.htm?path=medical-management-of-the-dialysis-patient-undergoing-surgery#H17\" class=\"medical medical_review\">&quot;Medical management of the dialysis patient undergoing surgery&quot;, section on 'Bleeding diathesis'</a>.) &#160; </p><p class=\"headingAnchor\" id=\"H416906689\"><span class=\"h2\">Management of hemostasis in hepatic insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with liver disease may have abnormalities in routine laboratory tests of coagulation, especially when liver synthetic function is significantly impaired and portal pressures are increased. These include prolongation of the prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT), as well as mild thrombocytopenia and elevated D-dimer. However, individuals with hepatic insufficiency also have abnormalities that increase the risk of thrombosis, and as a result laboratory abnormalities are poor predictors of bleeding risk. (See <a href=\"topic.htm?path=hemostatic-abnormalities-in-patients-with-liver-disease#H61498782\" class=\"medical medical_review\">&quot;Hemostatic abnormalities in patients with liver disease&quot;, section on 'Laboratory abnormalities'</a>.)</p><p>In selected patients with hepatic insufficiency who have clinically significant bleeding, vitamin K is administered to correct possible vitamin K deficiency; cryoprecipitate may be administered to maintain a fibrinogen concentration &gt;100 to 120 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/14\" class=\"abstract_t\">14</a>]. Also, platelets may be transfused if the patient is thrombocytopenic (eg, platelet count <span class=\"nowrap\">&lt;100,000/microL)</span>. An antifibrinolytic agent may be administered (eg, epsilon-aminocaproic acid [EACA] or <a href=\"topic.htm?path=tranexamic-acid-drug-information\" class=\"drug drug_general\">tranexamic acid</a> [TXA]) if point-of-care tests of coagulation (eg, thromboelastography [TEG]) indicate the presence of primary hyperfibrinolysis (<a href=\"image.htm?imageKey=SURG%2F58281%7ESURG%2F51767\" class=\"graphic graphic_figure graphicRef58281 graphicRef51767 \">figure 1A-B</a>) or secondary hyperfibrinolysis (<a href=\"image.htm?imageKey=SURG%2F58281%7ESURG%2F70388\" class=\"graphic graphic_figure graphicRef58281 graphicRef70388 \">figure 1A, 1C</a>). (See <a href=\"topic.htm?path=hemostatic-abnormalities-in-patients-with-liver-disease#H233835367\" class=\"medical medical_review\">&quot;Hemostatic abnormalities in patients with liver disease&quot;, section on 'General approach to managing bleeding'</a> and <a href=\"topic.htm?path=intraoperative-transfusion-of-blood-products-in-adults#H4126007645\" class=\"medical medical_review\">&quot;Intraoperative transfusion of blood products in adults&quot;, section on 'Point-of-care tests'</a>.) </p><p class=\"headingAnchor\" id=\"H1535228623\"><span class=\"h2\">Management of specific hemostatic disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Perioperative management of patients with inherited or acquired disorders that affect hemostasis is discussed in UpToDate topics for the specific disease. The most common examples are noted below.</p><p class=\"headingAnchor\" id=\"H3602358630\"><span class=\"h3\">Inherited conditions</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Von Willebrand disease (see <a href=\"topic.htm?path=treatment-of-von-willebrand-disease#H748861\" class=\"medical medical_review\">&quot;Treatment of von Willebrand disease&quot;, section on 'Surgery'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemophilia (see <a href=\"topic.htm?path=treatment-of-bleeding-and-perioperative-management-in-hemophilia-a-and-b#H3259236617\" class=\"medical medical_review\">&quot;Treatment of bleeding and perioperative management in hemophilia A and B&quot;, section on 'Elective surgery'</a> and <a href=\"topic.htm?path=treatment-of-bleeding-and-perioperative-management-in-hemophilia-a-and-b#H1255172857\" class=\"medical medical_review\">&quot;Treatment of bleeding and perioperative management in hemophilia A and B&quot;, section on 'Urgent/emergent surgery'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other congenital coagulation factor deficiencies (eg, factors XIII, XI, X, VII, V, II [prothrombin], fibrinogen) (see <a href=\"topic.htm?path=rare-inherited-coagulation-disorders#H908033\" class=\"medical medical_review\">&quot;Rare inherited coagulation disorders&quot;, section on 'Invasive procedure/surgery'</a> and <a href=\"topic.htm?path=disorders-of-fibrinogen#H27\" class=\"medical medical_review\">&quot;Disorders of fibrinogen&quot;, section on 'Management'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Congenital platelet disorders that cause platelet dysfunction or thrombocytopenia (see <a href=\"topic.htm?path=congenital-and-acquired-disorders-of-platelet-function#H35\" class=\"medical medical_review\">&quot;Congenital and acquired disorders of platelet function&quot;, section on 'Therapy'</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-unexplained-thrombocytopenia#H20171374\" class=\"medical medical_review\">&quot;Approach to the adult with unexplained thrombocytopenia&quot;, section on 'Causes of thrombocytopenia'</a>)</p><p/><p class=\"headingAnchor\" id=\"H3272726424\"><span class=\"h3\">Acquired disorders</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acquired platelet function disorders (see <a href=\"topic.htm?path=congenital-and-acquired-disorders-of-platelet-function#H35\" class=\"medical medical_review\">&quot;Congenital and acquired disorders of platelet function&quot;, section on 'Therapy'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acquired coagulation factor inhibitors (eg, autoantibodies against factors II, V, VII, VIII, IX, XI, or XIII) (see <a href=\"topic.htm?path=acquired-inhibitors-of-coagulation\" class=\"medical medical_review\">&quot;Acquired inhibitors of coagulation&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disseminated intravascular coagulation (DIC) (see <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults#H25\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;, section on 'Treatment'</a>)</p><p/><p class=\"headingAnchor\" id=\"H1521510609\"><span class=\"h2\">Preoperative autologous blood donation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We rarely use preoperative autologous donation (PAD) of blood with planned reinfusion during or shortly after the surgical procedure, due to the potential risk for clerical errors and wastage of unused PAD units. Additional drawbacks are expense and inconvenience (eg, the need for planning weeks before the proposed surgical procedure). In some institutions, PAD is offered as an autologous blood conservation option in candidates who are in relatively good health and are scheduled for a surgical procedure with expected blood loss &gt;500 to 1000 mL [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/15-17\" class=\"abstract_t\">15-17</a>]. Recombinant human erythropoietin may be used as an adjunct [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/1\" class=\"abstract_t\">1</a>]. Other details regarding PAD are discussed separately. (See <a href=\"topic.htm?path=surgical-blood-conservation-preoperative-autologous-blood-donation\" class=\"medical medical_review\">&quot;Surgical blood conservation: Preoperative autologous blood donation&quot;</a>.) &#160;</p><p class=\"headingAnchor\" id=\"H10487206\"><span class=\"h1\">INTRAOPERATIVE STRATEGIES</span></p><p class=\"headingAnchor\" id=\"H10487212\"><span class=\"h2\">Fluid management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We maintain perioperative normovolemia in all patients, but we avoid administration of large volumes of crystalloid solution (ie, we avoid a fixed volume approach to fluid therapy) in order to minimize dilutional anemia and coagulopathy. We maintain normovolemia by administering crystalloid to replace sensible and insensible losses (0.5 to 1 <span class=\"nowrap\">mL/kg</span> per hour), and we typically use a goal-directed approach to guide additional incremental fluid therapy during major surgical procedures. (See <a href=\"topic.htm?path=intraoperative-fluid-management#H254311346\" class=\"medical medical_review\">&quot;Intraoperative fluid management&quot;, section on 'Our approach to fluid management'</a>.)</p><p>For replacement of blood losses, either a balanced electrolyte crystalloid solution may be administered in a volume that is 1.5 times the amount of lost blood, or a colloid solution may be administered on a 1:1 volume basis until hemoglobin (Hgb) is &le;8 <span class=\"nowrap\">g/dL</span> or other criteria for red blood cell (RBC) transfusion are met. (See <a href=\"topic.htm?path=intraoperative-transfusion-of-blood-products-in-adults#H2495218495\" class=\"medical medical_review\">&quot;Intraoperative transfusion of blood products in adults&quot;, section on 'Red blood cells'</a> and <a href=\"topic.htm?path=intraoperative-fluid-management#H1058523188\" class=\"medical medical_review\">&quot;Intraoperative fluid management&quot;, section on 'Choosing fluid: Crystalloid, colloid, or blood'</a>.) </p><p>In patients who require massive transfusion of blood components (RBCs, plasma products, platelets), we minimize administration of crystalloid solution to avoid dilutional coagulopathy. (See <a href=\"topic.htm?path=massive-blood-transfusion\" class=\"medical medical_review\">&quot;Massive blood transfusion&quot;</a> and <a href=\"topic.htm?path=coagulopathy-associated-with-trauma#H62323474\" class=\"medical medical_review\">&quot;Coagulopathy associated with trauma&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H1848826462\"><span class=\"h2\">Temperature management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A blood warmer should be used for transfusion of all thawed or refrigerator-temperature blood products (eg, RBC units, plasma products, cryoprecipitate) to avoid hypothermia, which can lead to coagulopathy, bleeding, and additional transfusions [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/18-21\" class=\"abstract_t\">18-21</a>]. If necessary, other warming devices are routinely employed to maintain perioperative normothermia (temperature &ge;36&deg;C) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/22-25\" class=\"abstract_t\">22-25</a>]. These may include upper- and lower-body forced-air warming devices and blankets, and insulation water mattresses, as well as warming all intravenous (IV) fluids with a commercially available blood warming device. (See <a href=\"topic.htm?path=massive-blood-transfusion#H13\" class=\"medical medical_review\">&quot;Massive blood transfusion&quot;, section on 'Prevention of hypothermia'</a> and <a href=\"topic.htm?path=coagulopathy-associated-with-trauma#H299161\" class=\"medical medical_review\">&quot;Coagulopathy associated with trauma&quot;, section on 'Hypothermia'</a>.) </p><p class=\"headingAnchor\" id=\"H111418635\"><span class=\"h2\">Surgical blood conservation techniques</span></p><p class=\"headingAnchor\" id=\"H4716442\"><span class=\"h3\">Electrosurgery devices</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adequate hemostasis during surgical dissection is achieved by employing electrocautery to control bleeding from small vessels in most cases, as well as standard suturing techniques for larger vessels. These techniques are discussed separately. (See <a href=\"topic.htm?path=overview-of-electrosurgery#H4\" class=\"medical medical_review\">&quot;Overview of electrosurgery&quot;, section on 'Cutting and coagulation currents'</a>.)</p><p class=\"headingAnchor\" id=\"H4064190888\"><span class=\"h3\">Topical hemostatic agents and tissue adhesives</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In selected cases, topical hemostatic agents, tissue adhesives, and fibrin sealants are used as adjuncts to standard techniques and electrocautery to control bleeding. The mechanism of action, indications, and clinical applications of these adjuncts are reviewed separately. (See <a href=\"topic.htm?path=overview-of-topical-hemostatic-agents-and-tissues-adhesives\" class=\"medical medical_review\">&quot;Overview of topical hemostatic agents and tissues adhesives&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1011872377\"><span class=\"h3\">Acute normovolemic hemodilution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute normovolemic hemodilution (ANH) is a blood conservation technique appropriate for selected patients with normal initial hemoglobin levels who are expected to lose two or more units of blood (&ge;1000 mL) during surgery. It is safest when used in healthy, young adults, but can be used in other populations. It is a good option for Jehovah Witnesses who will consent to ANH if the blood is maintained in a closed circuit continuous flow. (See <a href=\"topic.htm?path=surgical-blood-conservation-intraoperative-hemodilution#H2\" class=\"medical medical_review\">&quot;Surgical blood conservation: Intraoperative hemodilution&quot;, section on 'Patient selection'</a>.)</p><p>ANH involves removal of blood from a patient shortly after induction of anesthesia, with maintenance of normovolemia using crystalloid <span class=\"nowrap\">and/or</span> colloid replacement fluid. Typically, one to three units of whole blood is removed, with 450 to 500 mL in each unit. This whole blood is reinfused into the patient during or shortly after the surgical procedure. Details regarding technical considerations are addressed separately. (See <a href=\"topic.htm?path=surgical-blood-conservation-intraoperative-hemodilution\" class=\"medical medical_review\">&quot;Surgical blood conservation: Intraoperative hemodilution&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H3362458230\"><span class=\"h3\">Intraoperative blood salvage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We employ intraoperative blood salvage from the surgical field during procedures that have a high likelihood of significant blood loss (&ge;1000 mL), based on evidence that allogeneic transfusion and associated complications can be avoided with a very low incidence of adverse events [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/26,27\" class=\"abstract_t\">26,27</a>]. Patient selection, specific indications, advantages, and potential complications of intraoperative blood salvage are discussed separately. (See <a href=\"topic.htm?path=surgical-blood-conservation-blood-salvage\" class=\"medical medical_review\">&quot;Surgical blood conservation: Blood salvage&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3894828099\"><span class=\"h2\">Selective use of procoagulant products</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In selected cases, a procoagulant agent is used to prevent or treat microvascular bleeding. This may include medications such as an antifibrinolytic or <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>, or a clotting factor product such as prothrombin complex concentrate (PCC), <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">fibrinogen concentrate</a>, or recombinant activated factor VII. Most of these products are associated with an increased thrombotic risk that must be balanced with the potential benefits.</p><p class=\"headingAnchor\" id=\"H3095259769\"><span class=\"h3\">Antifibrinolytics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lysine analog antifibrinolytic agents include epsilon-aminocaproic acid (EACA) and <a href=\"topic.htm?path=tranexamic-acid-drug-information\" class=\"drug drug_general\">tranexamic acid</a> (TXA). Availability of these agents is institution-specific. In the United States, EACA is used more commonly during cardiac surgery due to the higher cost of TXA and the greater association of TXA with postoperative seizures in this setting [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/28-32\" class=\"abstract_t\">28-32</a>]. However, TXA is the agent most extensively studied and used in most countries. Another antifibrinolytic agent, aprotinin, is a serine protease inhibitor that is not available in the United States, but is being reintroduced in Europe based on a reevaluation of studies comparing it with EACA or TXA [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/28,29\" class=\"abstract_t\">28,29</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and uses </strong>&ndash; An antifibrinolytic agent is routinely used in cardiac surgical procedures with cardiopulmonary bypass (CPB) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/8,28-30,33\" class=\"abstract_t\">8,28-30,33</a>]. Antifibrinolytics have also been used in selected major noncardiac surgical procedures that are likely to incur clinically significant blood loss (eg, liver transplantation or resection, major orthopedic procedures such as hip or knee arthroplasty or spine surgery, selected trauma patients), as well as for postpartum hemorrhage [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/1,28,29,33-40\" class=\"abstract_t\">1,28,29,33-40</a>]. In such cases, prophylactic administration of EACA or TXA is associated with reduced blood loss and reduced transfusion and may also be effective in managing postoperative bleeding [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/28,29\" class=\"abstract_t\">28,29</a>]. The presumed mechanism of reduced perioperative bleeding is a decrease in fibrinolysis.</p><p/><p class=\"bulletIndent1\">Dose regimens have not been standardized for IV administration of either EACA or TXA [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/28,41\" class=\"abstract_t\">28,41</a>]. TXA dosing should be reduced in patients with end-stage renal disease (ESRD) or moderate to severe renal insufficiency [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/42,43\" class=\"abstract_t\">42,43</a>].</p><p/><p class=\"bulletIndent1\">Details regarding patient selection and use and dosing of antifibrinolytic agents in specific surgical settings are available in separate topics: </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>(See <a href=\"topic.htm?path=cardiopulmonary-bypass-preparations-and-initiation#H1520349478\" class=\"medical medical_review\">&quot;Cardiopulmonary bypass: Preparations and initiation&quot;, section on 'Antifibrinolytic administration'</a>.) </p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>(See <a href=\"topic.htm?path=anesthesia-for-elective-spine-surgery-in-adults#H349560884\" class=\"medical medical_review\">&quot;Anesthesia for elective spine surgery in adults&quot;, section on 'Antifibrinolytics'</a>.)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>(See <a href=\"topic.htm?path=total-hip-arthroplasty#H706218868\" class=\"medical medical_review\">&quot;Total hip arthroplasty&quot;, section on 'Tranexamic acid'</a>.)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>(See <a href=\"topic.htm?path=initial-management-of-moderate-to-severe-hemorrhage-in-the-adult-trauma-patient#H1012810632\" class=\"medical medical_review\">&quot;Initial management of moderate to severe hemorrhage in the adult trauma patient&quot;, section on 'Antifibrinolytic agents'</a> and <a href=\"topic.htm?path=coagulopathy-associated-with-trauma\" class=\"medical medical_review\">&quot;Coagulopathy associated with trauma&quot;</a>.)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>(See <a href=\"topic.htm?path=postpartum-hemorrhage-medical-and-minimally-invasive-management#H2022038691\" class=\"medical medical_review\">&quot;Postpartum hemorrhage: Medical and minimally invasive management&quot;, section on 'Administer tranexamic acid'</a>.)</p><p/><p class=\"bulletIndent1\">Limited data are also available for topical application of TXA in selected settings. (See <a href=\"topic.htm?path=overview-of-topical-hemostatic-agents-and-tissues-adhesives#H175952525\" class=\"medical medical_review\">&quot;Overview of topical hemostatic agents and tissues adhesives&quot;, section on 'Tranexamic acid'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Risks</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prothrombotic effects &ndash; Due to concerns regarding prothrombotic effects, we do not administer IV antifibrinolytics in noncardiac surgical patients with risk factors for thrombosis (eg, a hypercoagulable condition), or in patients undergoing a vascular anastomosis such as flap coverage of a wound [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/29\" class=\"abstract_t\">29</a>]. Although thrombosis is less likely during cardiac surgery with CPB [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/30\" class=\"abstract_t\">30</a>], data suggest that use of TXA is associated with a higher incidence of stroke in patients at risk for this complication and in those undergoing cardiac valve replacement procedures [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/30,44\" class=\"abstract_t\">30,44</a>]. Therefore, individual patient-specific and procedure-specific risks for bleeding and transfusion are weighed against risk of stroke before administering an antifibrinolytic agent during cardiac surgery. &#160; </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Risk of seizures &ndash; TXA has been associated with postoperative seizures after cardiac surgery, and the risk may be dose-related [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/28-31,45\" class=\"abstract_t\">28-31,45</a>]. (See <a href=\"topic.htm?path=cardiopulmonary-bypass-preparations-and-initiation#H1520349478\" class=\"medical medical_review\">&quot;Cardiopulmonary bypass: Preparations and initiation&quot;, section on 'Antifibrinolytic administration'</a>.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hypotension with rapid injection &ndash; Rapid IV administration of EACA should be avoided since this may induce hypotension, as well as bradycardia or other arrhythmias [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/46\" class=\"abstract_t\">46</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Anaphylaxis &ndash; Cases of allergic reactions have been reported with use of TXA or EACA, including anaphylaxis [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/46,47\" class=\"abstract_t\">46,47</a>]. (See <a href=\"topic.htm?path=perioperative-anaphylaxis-clinical-manifestations-etiology-and-management#H12\" class=\"medical medical_review\">&quot;Perioperative anaphylaxis: Clinical manifestations, etiology, and management&quot;, section on 'Other agents'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2826693653\"><span class=\"h3\">Desmopressin (DDAVP)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">Desmopressin</a> (1-deamino-8-D-arginine vasopressin [DDAVP]) is a synthetic analogue of the antidiuretic hormone vasopressin that increases plasma levels of von Willebrand factor, factor VIII, and tissue-type plasminogen activator (tPA) by causing these factors to be released from platelets and endothelial cells.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and uses </strong>&ndash; In consultation with a hematologist, DDAVP is administered prophylactically for minor surgery or treatment of mild bleeding in selected patients with von Willebrand disease (type 1) or hemophilia A for whom a positive response has been demonstrated previously [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/48\" class=\"abstract_t\">48</a>] (<a href=\"image.htm?imageKey=HEME%2F110532\" class=\"graphic graphic_table graphicRef110532 \">table 6</a>). (See <a href=\"topic.htm?path=treatment-of-von-willebrand-disease#H8\" class=\"medical medical_review\">&quot;Treatment of von Willebrand disease&quot;, section on 'Desmopressin (DDAVP)'</a> and <a href=\"topic.htm?path=treatment-of-von-willebrand-disease#H748861\" class=\"medical medical_review\">&quot;Treatment of von Willebrand disease&quot;, section on 'Surgery'</a> and <a href=\"topic.htm?path=treatment-of-bleeding-and-perioperative-management-in-hemophilia-a-and-b#H3527578270\" class=\"medical medical_review\">&quot;Treatment of bleeding and perioperative management in hemophilia A and B&quot;, section on 'DDAVP for mild hemophilia A'</a>.) </p><p/><p class=\"bulletIndent1\">DDAVP has also been administered to treat clinically significant intraoperative microvascular bleeding in patients with acquired von Willebrand disease due to autoimmune disorders, neoplastic disorders, uremia, aortic stenosis, or presence of a mechanical ventricular assist device [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/49,50\" class=\"abstract_t\">49,50</a>]. (See <a href=\"topic.htm?path=acquired-von-willebrand-syndrome#H222500770\" class=\"medical medical_review\">&quot;Acquired von Willebrand syndrome&quot;, section on 'Treatment of acute bleeding'</a>.) &#160;</p><p/><p class=\"bulletIndent1\">Furthermore, IV DDAVP has been administered to treat clinically significant intraoperative microvascular bleeding in patients with platelet dysfunction due to uremia. (See <a href=\"topic.htm?path=platelet-dysfunction-in-uremia#H7704093\" class=\"medical medical_review\">&quot;Platelet dysfunction in uremia&quot;, section on 'Desmopressin (DDAVP)'</a>.)</p><p/><p class=\"bulletIndent1\">Some clinicians administer DDAVP to treat intractable intraoperative microvascular bleeding presumed to be due to other causes of platelet dysfunction (eg, hypothermia, acidosis, recent <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> use, CPB) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/1,50\" class=\"abstract_t\">1,50</a>]. Limited animal and human data indicate that DDAVP may improve platelet function and reduce blood loss in these circumstances [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/51-56\" class=\"abstract_t\">51-56</a>], although studies are not consistent [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/57\" class=\"abstract_t\">57</a>]. A 2017 meta-analysis of the efficacy of DDAVP in reducing perioperative blood loss and the need for RBC transfusion in adults undergoing cardiac surgery concluded that reduction in transfused RBC volume is small and unlikely to be clinically significant compared with placebo [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/58\" class=\"abstract_t\">58</a>]. (See <a href=\"topic.htm?path=coagulopathy-associated-with-trauma#H83049587\" class=\"medical medical_review\">&quot;Coagulopathy associated with trauma&quot;, section on 'Pharmaceutical hemostatic agents'</a>.) &#160; &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dosing </strong>&ndash; The IV DDAVP dose is 0.3 <span class=\"nowrap\">mcg/kg,</span> administered slowly over 30 minutes to minimize the side effects of hypertension, hypotension, and flushing (<a href=\"image.htm?imageKey=HEME%2F110532\" class=\"graphic graphic_table graphicRef110532 \">table 6</a>). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Risks</strong> &ndash; In addition to hypertension, hypotension, and flushing, possible adverse side effects include fluid overload, hyponatremia, and rare thrombotic events (<a href=\"image.htm?imageKey=HEME%2F110532\" class=\"graphic graphic_table graphicRef110532 \">table 6</a>). Monitoring of serum sodium is prudent in patients receiving more than one or two doses.</p><p/><p class=\"headingAnchor\" id=\"H2978398940\"><span class=\"h3\">Prothrombin complex concentrate (PCC)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and uses</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Uses of unactivated PCC </strong>&ndash; Unactivated PCC contain clotting factors (factors II, VII, IX, and X for four-factor products) in their inactive, precursor state (<a href=\"image.htm?imageKey=HEME%2F94210\" class=\"graphic graphic_table graphicRef94210 \">table 7</a>). When PCC is given, a four-factor product should be used. If only a three-factor product is available, it may require supplementation with FFP. PCCs carry a prothrombotic risk and are only used if the benefits are thought to outweigh the risks. An unactivated PCC product is the preferred treatment in patients requiring immediate reversal of anticoagulation with a vitamin K antagonist (eg, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>) for urgent surgery, particularly in the setting of intracranial hemorrhage. The efficacy of unactivated PCC versus plasma for coagulopathy and bleeding after CPB is under investigation [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/50,59-62\" class=\"abstract_t\">50,59-62</a>]. If the only available PCC is a three-factor product which contains high levels of factors II, IX, and X, then supplemental factor VII may be administered. (See <a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr#H428500\" class=\"medical medical_review\">&quot;Management of warfarin-associated bleeding or supratherapeutic INR&quot;, section on 'PCC products, efficacy, risks'</a> and <a href=\"topic.htm?path=reversal-of-anticoagulation-in-warfarin-associated-intracerebral-hemorrhage#H10\" class=\"medical medical_review\">&quot;Reversal of anticoagulation in warfarin-associated intracerebral hemorrhage&quot;, section on 'Unactivated prothrombin-complex concentrates'</a>.)</p><p/><p class=\"bulletIndent2\">Most PCC preparations contain low doses of heparin to prevent clotting factor activation, as well as variable amounts of protein C and protein S. Advantages of PCCs over Fresh Frozen Plasma (FFP) include rapid administration in a small volume, resulting in more rapid reversal of the anticoagulant effect and avoidance of risks associated with FFP such as volume overload and transfusion reactions [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/50,59-63\" class=\"abstract_t\">50,59-63</a>]. (See <a href=\"topic.htm?path=intraoperative-transfusion-of-blood-products-in-adults#H4129789782\" class=\"medical medical_review\">&quot;Intraoperative transfusion of blood products in adults&quot;, section on 'Plasma'</a> and <a href=\"topic.htm?path=plasma-derivatives-and-recombinant-dna-produced-coagulation-factors\" class=\"medical medical_review\">&quot;Plasma derivatives and recombinant DNA-produced coagulation factors&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Uses of activated PCC</strong> &ndash; Activated PCC (aPCC) contain clotting factors II, VII, IX, and X; factor VII is mostly in the activated state (<a href=\"image.htm?imageKey=HEME%2F94210\" class=\"graphic graphic_table graphicRef94210 \">table 7</a>). The aPCC product available in the United States is Factor Eight Inhibitor Bypassing Activity (FEIBA). PCCs carry a prothrombotic risk and are only used if the benefits are thought to outweigh the risks. Intraoperative indications include use for emergency surgery in a bleeding patient with a factor VIII inhibitor, or for reversal of certain anticoagulants (eg, <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a>). FEIBA should not be used to reverse <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> anticoagulation because the risks of a thromboembolic event outweigh the benefits. (See <a href=\"topic.htm?path=plasma-derivatives-and-recombinant-dna-produced-coagulation-factors#H16\" class=\"medical medical_review\">&quot;Plasma derivatives and recombinant DNA-produced coagulation factors&quot;, section on 'Activated PCCs'</a> and <a href=\"topic.htm?path=fondaparinux-dosing-and-adverse-effects#H3331234277\" class=\"medical medical_review\">&quot;Fondaparinux: Dosing and adverse effects&quot;, section on 'Bleeding/emergency surgery'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dosing </strong>&ndash; The dose is tailored to the individual patient&rsquo;s needs based on clinical indications and laboratory testing. Ideally, point-of-care laboratory tests are obtained to monitor overall hemostatic function (<a href=\"image.htm?imageKey=SURG%2F58281\" class=\"graphic graphic_figure graphicRef58281 \">figure 1A</a>) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/64\" class=\"abstract_t\">64</a>]. (See <a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr#H428500\" class=\"medical medical_review\">&quot;Management of warfarin-associated bleeding or supratherapeutic INR&quot;, section on 'PCC products, efficacy, risks'</a> and <a href=\"topic.htm?path=intraoperative-transfusion-of-blood-products-in-adults#H4126007645\" class=\"medical medical_review\">&quot;Intraoperative transfusion of blood products in adults&quot;, section on 'Point-of-care tests'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Risks </strong>&ndash; Although PCC products have been used to correct severe intractable microvascular bleeding during surgery, human data for safety (particularly prothrombotic risk) for this indication are limited [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/60,65-67\" class=\"abstract_t\">60,65-67</a>]. Hypofibrinogenemia and thrombocytopenia are typically treated before use of a PCC product. </p><p/><p class=\"bulletIndent1\">Prothrombotic risks of PCC product administration increase with repeat or excessive dosing. This risk extends well into the postoperative period due to the long half-life (60 to 72 hours) of factor II, a component of PCC products [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/64\" class=\"abstract_t\">64</a>]. (See <a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr#H428500\" class=\"medical medical_review\">&quot;Management of warfarin-associated bleeding or supratherapeutic INR&quot;, section on 'PCC products, efficacy, risks'</a>.)</p><p/><p class=\"bulletIndent1\">In particular, activated PCC (aPCC) products such as FEIBA have a very high prothrombotic risk because they contain activated factor VII. For an individual patient, this risk must be balanced with the risks of continued bleeding. (See <a href=\"topic.htm?path=plasma-derivatives-and-recombinant-dna-produced-coagulation-factors#H16\" class=\"medical medical_review\">&quot;Plasma derivatives and recombinant DNA-produced coagulation factors&quot;, section on 'Activated PCCs'</a>.)</p><p/><p class=\"bulletIndent1\">Some PCC products contain heparin and should not be used in an individual with a history of heparin-induced thrombocytopenia (HIT).</p><p/><p class=\"headingAnchor\" id=\"H32315478\"><span class=\"h3\">Fibrinogen concentrate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Virally-inactivated human fibrinogen concentrates have been developed from human pooled plasma for use in individuals with fibrinogen deficiency <span class=\"nowrap\">and/or</span> dysfunction (eg, RiaSTAP, Fibryga, Haemocomplettan). Use of <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">fibrinogen concentrate</a> is increasing because, due to its manufacturing process, there is a lower risk of infectious complications compared with cryoprecipitate [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/68\" class=\"abstract_t\">68</a>]. (See <a href=\"topic.htm?path=clinical-use-of-cryoprecipitate#H2785910148\" class=\"medical medical_review\">&quot;Clinical use of Cryoprecipitate&quot;, section on 'Risks and adverse events'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and uses </strong>&ndash; In a patient with a fibrinogen disorder, treatment with a <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">fibrinogen concentrate</a> is appropriate to treat or prevent bleeding during surgery. (See <a href=\"topic.htm?path=disorders-of-fibrinogen#H1979341027\" class=\"medical medical_review\">&quot;Disorders of fibrinogen&quot;, section on 'Fibrinogen concentrate: Dosing and monitoring'</a>.):</p><p/><p class=\"bulletIndent1\">It may also be reasonable to administer <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">fibrinogen concentrate</a> to treat intractable intraoperative coagulopathy in selected surgical settings (eg, trauma surgery, cardiac surgery with CPB, thoracoabdominal aortic replacement surgery, liver transplantation, severe postpartum hemorrhage) if a low fibrinogen concentration (eg, &lt;120 <span class=\"nowrap\">mg/dL)</span> is documented or strongly suspected [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/50,61,69-74\" class=\"abstract_t\">50,61,69-74</a>]. Administration of fibrinogen concentrate in these settings is more common in Europe than in the United States; the European Society of Anesthesia (ESA) guidelines suggest use of fibrinogen concentrate to maintain a target concentration &gt;150 to 200 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/65\" class=\"abstract_t\">65</a>]. Proponents argue that the baseline concentration of fibrinogen is relatively low, and there are no fibrinogen stores to be mobilized; thus, fibrinogen is the first coagulation protein to become critically low during intraoperative bleeding [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/50,75\" class=\"abstract_t\">50,75</a>]. In a 2016 meta-analysis that primarily included cardiac surgical patients, administration of fibrinogen concentrate resulted in less bleeding, fewer units of RBCs transfused (by approximately one unit), and a lower incidence of all-cause mortality compared with placebo or other hemostatic treatments (1035 patients; 14 trials) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/74\" class=\"abstract_t\">74</a>]. Conclusions were limited by moderate to high risk of bias in the included studies. In contrast, in a 2017 randomized trial conducted in 120 patients undergoing complex cardiac surgical procedures, a single dose of fibrinogen concentrate targeting a plasma concentration of 250 <span class=\"nowrap\">mg/dL</span> did not significantly reduce intraoperative blood loss, and there was a nonsignificant trend toward more adverse events in the fibrinogen group, including stroke, myocardial infarction, and death [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/76\" class=\"abstract_t\">76</a>]. (See <a href=\"topic.htm?path=coagulopathy-associated-with-trauma#H3046566862\" class=\"medical medical_review\">&quot;Coagulopathy associated with trauma&quot;, section on 'Factor levels'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dosing </strong>&ndash; For patients with documented low fibrinogen concentration, dose of <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">fibrinogen concentrate</a> is calculated according to the target fibrinogen concentration, as described separately. (See <a href=\"topic.htm?path=disorders-of-fibrinogen#H1979341027\" class=\"medical medical_review\">&quot;Disorders of fibrinogen&quot;, section on 'Fibrinogen concentrate: Dosing and monitoring'</a>.):</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Risks</strong> &ndash; Thromboembolic complications can occur with <a href=\"topic.htm?path=fibrinogen-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">fibrinogen concentrate</a>, particularly in pregnant patients or in those with a thrombotic fibrinogen variant. We avoid overcorrection of fibrinogen deficiency to minimize this risk. Dosing is typically monitored with POC testing, with the goal of achieving effective hemostasis while avoiding a hypercoagulable state (<a href=\"image.htm?imageKey=SURG%2F58281%7ESURG%2F58977\" class=\"graphic graphic_figure graphicRef58281 graphicRef58977 \">figure 1A, 1D</a>) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/72,73\" class=\"abstract_t\">72,73</a>]. If POC testing is not available, the plasma fibrinogen level can be monitored. (See <a href=\"topic.htm?path=intraoperative-transfusion-of-blood-products-in-adults#H4126007645\" class=\"medical medical_review\">&quot;Intraoperative transfusion of blood products in adults&quot;, section on 'Point-of-care tests'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H1302813894\"><span class=\"h3\">Recombinant activated factor VII (rFVIIa)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recombinant activated factor VII (rFVIIa) acts on platelet surfaces via tissue factor-dependent and independent mechanisms to generate a high local concentration of thrombin (ie, a thrombin burst) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/77\" class=\"abstract_t\">77</a>]. (See <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects#H3\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;, section on 'Mechanism of action'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and uses </strong>&ndash; rFVIIa is licensed for treatment of patients with hemophilia who have developed an inhibitor to Factor VIII or Factor IX.</p><p/><p class=\"bulletIndent1\">In rare circumstances, rFVIIa is administered to a non-hemophilic patient during surgery. Administration is considered to avoid further transfusion if in situations where blood products are not available (eg, lack of compatible red cells), for patients who refuse blood products, and if life-threatening coagulopathic bleeding has not responded to appropriate transfusion and other conventional therapy. (See <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects#H12\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;, section on 'Off-label experience'</a>.):</p><p/><p class=\"bulletIndent1\">Although information regarding efficacy of rFVIIa is largely anecdotal, systematic reviews have reported a reduction in requirements for additional transfusions [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/78-81\" class=\"abstract_t\">78-81</a>]. However, there is some risk of thromboembolic events, as noted below, and no survival benefit. (See <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects#H22768015\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;, section on 'Meta-analyses of off-label uses'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dosing </strong>&ndash; Cautious dosing of rFVIIa is employed since optimal dosing for this off-label use is unknown. We start with administration of small incremental doses of 10 to 30 <span class=\"nowrap\">mcg/kg</span> approximately every 15 minutes to a total dose of up to 90 <span class=\"nowrap\">mcg/kg</span>. Risk for the thrombotic complications are likely to be less when low doses (eg, 10 to 30 <span class=\"nowrap\">mcg/kg)</span> are administered [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/79,82\" class=\"abstract_t\">79,82</a>].</p><p/><p class=\"bulletIndent1\">For massive coagulopathic bleeding, an initial dose of 90 <span class=\"nowrap\">mcg/kg</span> of rFVIIa may be appropriate. Clinical dosing practices vary widely because data are lacking regarding optimal dosing of rFVIIa in a given individual or situation, and there is no laboratory test to monitor drug effect or efficacy [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/83\" class=\"abstract_t\">83</a>]. (See <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects#H24\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;, section on 'Dosing and laboratory monitoring'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Risks</strong> &ndash; An increased risk of arterial thromboembolic events has been noted in some trials of off-label use of rFVIIa, particularly in patients with intracranial hemorrhage and those undergoing cardiac surgery [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/78-81\" class=\"abstract_t\">78-81</a>]. Such off-label use of rFVIIa might actually be associated with increased morbidity (eg, renal failure) and mortality, especially in older patients and with higher doses [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/50,79,84-86\" class=\"abstract_t\">50,79,84-86</a>]. </p><p/><p class=\"bulletIndent1\">Thromboembolic events rarely occur when rFVIIa is used for approved indications (eg, hemophilia A or B with a factor inhibitor) unless the patient has pre-existing risk factors for thrombosis. (See <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects#H25\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;, section on 'Safety issues'</a>.)</p><p/><p class=\"bulletIndent1\">Data are lacking regarding appropriate settings, efficacy, side effects, and integration of rFVIIa with other transfusion therapies. (See <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects#H11\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;, section on 'Regulatory concerns and costs'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3840640628\"><span class=\"h1\">REFUSAL OR LIMITED AVAILABILITY OF BLOOD</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The followers of the Jehovah&rsquo;s Witness religious faith typically refuse to accept some or all types of allogeneic blood component transfusions. However, there may be areas of discretion for individual patients regarding alternative strategies to manage anemia and hemorrhage, such as preoperative use of erythropoietin, preoperative autologous donation (PAD), intraoperative blood salvage, or intraoperative acute normovolemic hemodilution [ANH] (<a href=\"image.htm?imageKey=HEME%2F67244\" class=\"graphic graphic_table graphicRef67244 \">table 8</a>) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/87,88\" class=\"abstract_t\">87,88</a>]. These alternatives are discussed during the preoperative informed discussion and are employed when possible (<a href=\"image.htm?imageKey=HEME%2F106229\" class=\"graphic graphic_table graphicRef106229 \">table 9</a>). (See <a href=\"#H1710529857\" class=\"local\">'Correction of anemia or thrombocytopenia'</a> above and <a href=\"#H3362458230\" class=\"local\">'Intraoperative blood salvage'</a> above and <a href=\"#H1011872377\" class=\"local\">'Acute normovolemic hemodilution'</a> above.)</p><p>Similar strategies for blood management are applicable when blood is limited or unavailable in other situations (eg, previously transfused patients with multiple alloantibodies or incompatible crossmatching for other reasons, wounded soldiers on the battlefield, surgical procedure performed in areas of limited [or highly infectious] blood supply) [<a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/89\" class=\"abstract_t\">89</a>]. (See <a href=\"topic.htm?path=the-approach-to-the-patient-who-refuses-blood-transfusion\" class=\"medical medical_review\">&quot;The approach to the patient who refuses blood transfusion&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10487392\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The preanesthetic consultation provides an opportunity to assess and minimize risks for bleeding and transfusion. It may be appropriate to postpone an elective procedure to treat a condition (eg, anemia, coagulopathy) if the benefits outweigh the risks. (See <a href=\"#H2373181178\" class=\"local\">'Preoperative strategies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A baseline hemoglobin measurement is suggested for patients &ge;65 years old for major surgery, and for any patient undergoing a procedure expected to result in significant blood loss, but is unnecessary for patients undergoing minor surgery unless the history suggests anemia. No additional laboratory testing is required unless the presence of a bleeding disorder is suspected. If history or physical examination suggests a bleeding disorder, appropriate screening tests include international normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count. (See <a href=\"#H2354604631\" class=\"local\">'Selective laboratory testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preoperative strategies to minimize transfusion risks include appropriate therapy for the following conditions:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Management of medications affecting hemostasis (eg, anticoagulants, antiplatelet agents, herbal supplements) (see <a href=\"#H2290460988\" class=\"local\">'Management of medications affecting hemostasis'</a> above and <a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants\" class=\"medical medical_review\">&quot;Perioperative management of patients receiving anticoagulants&quot;</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Treatment of anemia when feasible (see <a href=\"#H2062982004\" class=\"local\">'Correction of anemia in selected patients'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Therapy to increase the platelet count for selected procedures (see <a href=\"#H3787518421\" class=\"local\">'Treatment of thrombocytopenia for selected procedures'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Reversal of a vitamin K antagonist or treatment of vitamin K deficiency (see <a href=\"#H988137511\" class=\"local\">'Treatment of vitamin K deficiency'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Management of anemia and hemostatic abnormalities associated with renal insufficiency (see <a href=\"#H2401243333\" class=\"local\">'Management of anemia and hemostasis in renal insufficiency'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Management of hemostatic abnormalities associated with hepatic insufficiency (see <a href=\"#H416906689\" class=\"local\">'Management of hemostasis in hepatic insufficiency'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Management of inherited or acquired disorders that affect hemostasis (see <a href=\"#H1535228623\" class=\"local\">'Management of specific hemostatic disorders'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Perioperative strategies to minimize transfusions include attention to volume status, temperature, and local hemostasis in all patients, and use of acute normovolemic hemodilution in selected patients. In some cases, administration of systemic agents or clotting factor products may be appropriate. (See <a href=\"#H10487206\" class=\"local\">'Intraoperative strategies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who refuse blood transfusion or when blood availability is limited, alternative strategies to manage anemia and hemorrhage are employed when possible. (See <a href=\"#H3840640628\" class=\"local\">'Refusal or limited availability of blood'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/1\" class=\"nounderline abstract_t\">American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology 2015; 122:241.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/2\" class=\"nounderline abstract_t\">Committee on Standards and Practice Parameters, Apfelbaum JL, Connis RT, et al. Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Anesthesiology 2012; 116:522.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/3\" class=\"nounderline abstract_t\">Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008; 140:496.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/4\" class=\"nounderline abstract_t\">De Hert S, Imberger G, Carlisle J, et al. Preoperative evaluation of the adult patient undergoing non-cardiac surgery: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2011; 28:684.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/5\" class=\"nounderline abstract_t\">Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. Transfusion 2007; 47:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/6\" class=\"nounderline abstract_t\">Mu&ntilde;oz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 2017; 72:233.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/7\" class=\"nounderline abstract_t\">Kotz&eacute; A, Harris A, Baker C, et al. British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre-Operative Anaemia. Br J Haematol 2015; 171:322.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/8\" class=\"nounderline abstract_t\">Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/9\" class=\"nounderline abstract_t\">Froessler B, Palm P, Weber I, et al. The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial. Ann Surg 2016; 264:41.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/10\" class=\"nounderline abstract_t\">Rineau E, Stoyanov A, Samson E, et al. Patient Blood Management in Major Orthopedic Surgery: Less Erythropoietin and More Iron? Anesth Analg 2017; 125:1597.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/11\" class=\"nounderline abstract_t\">Zeidler K, Arn K, Senn O, et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion 2011; 51:2269.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/12\" class=\"nounderline abstract_t\">Leffell MS, Kim D, Vega RM, et al. Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation 2014; 97:525.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/13\" class=\"nounderline abstract_t\">Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost 2010; 36:34.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/14\" class=\"nounderline abstract_t\">Shah NL, Intagliata NM, Northup PG, et al. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol 2014; 11:675.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/15\" class=\"nounderline abstract_t\">Bouchard D, Marcheix B, Al-Shamary S, et al. Preoperative autologous blood donation reduces the need for allogeneic blood products: a prospective randomized study. Can J Surg 2008; 51:422.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/16\" class=\"nounderline abstract_t\">Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am 2002; 84-A:1299.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/17\" class=\"nounderline abstract_t\">Kanter MH, van Maanen D, Anders KH, et al. Preoperative autologous blood donations before elective hysterectomy. JAMA 1996; 276:798.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/18\" class=\"nounderline abstract_t\">Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56:1221.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/19\" class=\"nounderline abstract_t\">Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/20\" class=\"nounderline abstract_t\">Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008; 65:951.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/21\" class=\"nounderline abstract_t\">Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94:199.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/22\" class=\"nounderline abstract_t\">John M, Ford J, Harper M. Peri-operative warming devices: performance and clinical application. Anaesthesia 2014; 69:623.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/23\" class=\"nounderline abstract_t\">Perl T, Br&auml;uer A, Quintel M. Prevention of perioperative hypothermia with forced-air warming systems and upper-body blankets. Surg Technol Int 2006; 15:19.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/24\" class=\"nounderline abstract_t\">Madrid E, Urr&uacute;tia G, Roqu&eacute; i Figuls M, et al. Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults. Cochrane Database Syst Rev 2016; 4:CD009016.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/25\" class=\"nounderline abstract_t\">Sessler DI. Perioperative thermoregulation and heat balance. Lancet 2016; 387:2655.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/26\" class=\"nounderline abstract_t\">Carless PA, Henry DA, Moxey AJ, et al. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2010; :CD001888.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/27\" class=\"nounderline abstract_t\">DeAndrade D, Waters JH, Triulzi DJ, et al. Very low rate of patient-related adverse events associated with the use of intraoperative cell salvage. Transfusion 2016; 56:2768.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/28\" class=\"nounderline abstract_t\">Levy JH, Koster A, Quinones QJ, et al. Antifibrinolytic Therapy and Perioperative Considerations. Anesthesiology 2018; 128:657.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/29\" class=\"nounderline abstract_t\">Gerstein NS, Brierley JK, Windsor J, et al. Antifibrinolytic Agents in Cardiac and Noncardiac Surgery: A Comprehensive Overview and Update. J Cardiothorac Vasc Anesth 2017; 31:2183.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/30\" class=\"nounderline abstract_t\">Myles PS, Smith JA, Forbes A, et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med 2017; 376:136.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/31\" class=\"nounderline abstract_t\">Lecker I, Wang DS, Whissell PD, et al. Tranexamic acid-associated seizures: Causes and treatment. Ann Neurol 2016; 79:18.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/32\" class=\"nounderline abstract_t\">Raghunathan K, Connelly NR, Kanter GJ. &epsilon;-Aminocaproic acid and clinical value in cardiac anesthesia. J Cardiothorac Vasc Anesth 2011; 25:16.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/33\" class=\"nounderline abstract_t\">Koster A, Faraoni D, Levy JH. Antifibrinolytic Therapy for Cardiac Surgery: An Update. Anesthesiology 2015; 123:214.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/34\" class=\"nounderline abstract_t\">Molenaar IQ, Warnaar N, Groen H, et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007; 7:185.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/35\" class=\"nounderline abstract_t\">Poeran J, Rasul R, Suzuki S, et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014; 349:g4829.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/36\" class=\"nounderline abstract_t\">Zufferey PJ, Lanoisel&eacute;e J, Chapelle C, et al. Intravenous Tranexamic Acid Bolus plus Infusion Is Not More Effective than a Single Bolus in Primary Hip Arthroplasty: A Randomized Controlled Trial. Anesthesiology 2017; 127:413.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/37\" class=\"nounderline abstract_t\">Zufferey P, Merquiol F, Laporte S, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006; 105:1034.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/38\" class=\"nounderline abstract_t\">Berenholtz SM, Pham JC, Garrett-Mayer E, et al. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. Spine (Phila Pa 1976) 2009; 34:2096.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/39\" class=\"nounderline abstract_t\">Gill JB, Chin Y, Levin A, Feng D. The use of antifibrinolytic agents in spine surgery. A meta-analysis. J Bone Joint Surg Am 2008; 90:2399.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/40\" class=\"nounderline abstract_t\">Yuan C, Zhang H, He S. Efficacy and safety of using antifibrinolytic agents in spine surgery: a meta-analysis. PLoS One 2013; 8:e82063.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/41\" class=\"nounderline abstract_t\">Goobie SM, Frank SM. Tranexamic Acid: What Is Known and Unknown, and Where Do We Go From Here? Anesthesiology 2017; 127:405.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/42\" class=\"nounderline abstract_t\">Jerath A, Yang QJ, Pang KS, et al. Tranexamic Acid Dosing for Cardiac Surgical Patients With Chronic Renal Dysfunction: A New Dosing Regimen. Anesth Analg 2018.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/43\" class=\"nounderline abstract_t\">Andersson L, Eriksson O, Hedlund PO, et al. Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Res 1978; 6:83.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/44\" class=\"nounderline abstract_t\">Zhou ZF, Zhang FJ, Huo YF, et al. Intraoperative tranexamic acid is associated with postoperative stroke in patients undergoing cardiac surgery. PLoS One 2017; 12:e0177011.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/45\" class=\"nounderline abstract_t\">Couture P, Lebon JS, Lalibert&eacute; &Eacute;, et al. Low-Dose Versus High-Dose Tranexamic Acid Reduces the Risk of Nonischemic Seizures After Cardiac Surgery With Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2017; 31:1611.</a></li><li class=\"breakAll\">https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=1c5bc1dd-e9ec-44c1-9281-67ad482315d9&amp;type=pdf&amp;name=1c5bc1dd-e9ec-44c1-9281-67ad482315d9 (version 9.2017) (Accessed on December 06, 2017).</li><li class=\"breakAll\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019281s041lbl.pdf (Accessed on December 06, 2017).</li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/48\" class=\"nounderline abstract_t\">Leebeek FWG, Eikenboom JCJ. Von Willebrand's Disease. N Engl J Med 2017; 376:701.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/49\" class=\"nounderline abstract_t\">Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117:6777.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/50\" class=\"nounderline abstract_t\">Pagano D, Milojevic M, Meesters MI, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018; 53:79.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/51\" class=\"nounderline abstract_t\">Hanke AA, Dellweg C, Kienbaum P, et al. Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: an in vitro study using multiple electrode aggregometry*. Anaesthesia 2010; 65:688.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/52\" class=\"nounderline abstract_t\">Ying CL, Tsang SF, Ng KF. The potential use of desmopressin to correct hypothermia-induced impairment of primary haemostasis--an in vitro study using PFA-100. Resuscitation 2008; 76:129.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/53\" class=\"nounderline abstract_t\">Sheridan DP, Card RT, Pinilla JC, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994; 37:33.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/54\" class=\"nounderline abstract_t\">Despotis GJ, Levine V, Saleem R, et al. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 1999; 354:106.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/55\" class=\"nounderline abstract_t\">Wademan BH, Galvin SD. Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. Interact Cardiovasc Thorac Surg 2014; 18:360.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/56\" class=\"nounderline abstract_t\">Crescenzi G, Landoni G, Biondi-Zoccai G, et al. Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology 2008; 109:1063.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/57\" class=\"nounderline abstract_t\">Orlov D, McCluskey SA, Callum J, et al. Utilization and Effectiveness of Desmopressin Acetate After Cardiac Surgery Supplemented With Point-of-Care Hemostatic Testing: A Propensity-Score-Matched Analysis. J Cardiothorac Vasc Anesth 2017; 31:883.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/58\" class=\"nounderline abstract_t\">Desborough MJ, Oakland K, Brierley C, et al. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev 2017; 7:CD001884.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/59\" class=\"nounderline abstract_t\">Smith MM, Ashikhmina E, Brinkman NJ, Barbara DW. Perioperative Use of Coagulation Factor Concentrates in Patients Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth 2017; 31:1810.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/60\" class=\"nounderline abstract_t\">Ghadimi K, Levy JH, Welsby IJ. Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. Anesth Analg 2016; 122:1287.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/61\" class=\"nounderline abstract_t\">Ghadimi K, Welsby IJ. Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery. J Cardiothorac Vasc Anesth 2018; 32:558.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/62\" class=\"nounderline abstract_t\">Goldhammer JE, Herman CR. A Split From Conventional Blood Component Therapy? J Cardiothorac Vasc Anesth 2018; 32:168.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/63\" class=\"nounderline abstract_t\">Sun GH, Patel V, Moreno-Duarte I, et al. Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation. J Cardiothorac Vasc Anesth 2018; 32:161.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/64\" class=\"nounderline abstract_t\">Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8:149.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/65\" class=\"nounderline abstract_t\">Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30:270.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/66\" class=\"nounderline abstract_t\">Fries D. The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. Transfusion 2013; 53 Suppl 1:91S.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/67\" class=\"nounderline abstract_t\">Weber CF, G&ouml;rlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117:531.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/68\" class=\"nounderline abstract_t\">S&oslash;rensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149:834.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/69\" class=\"nounderline abstract_t\">Jensen NH, Stensballe J, Afshari A. Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review. Acta Anaesthesiol Scand 2016; 60:1033.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/70\" class=\"nounderline abstract_t\">Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118:40.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/71\" class=\"nounderline abstract_t\">Wikkels&oslash; A, Lunde J, Johansen M, et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev 2013; :CD008864.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/72\" class=\"nounderline abstract_t\">Sch&ouml;chl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14:R55.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/73\" class=\"nounderline abstract_t\">Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256:476.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/74\" class=\"nounderline abstract_t\">Fominskiy E, Nepomniashchikh VA, Lomivorotov VV, et al. Efficacy and Safety of Fibrinogen Concentrate in Surgical Patients: A Meta-Analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth 2016; 30:1196.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/75\" class=\"nounderline abstract_t\">Hiippala ST, Myllyl&auml; GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81:360.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/76\" class=\"nounderline abstract_t\">Bilecen S, de Groot JA, Kalkman CJ, et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial. JAMA 2017; 317:738.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/77\" class=\"nounderline abstract_t\">Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006; 32 Suppl 1:77.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/78\" class=\"nounderline abstract_t\">Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154:529.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/79\" class=\"nounderline abstract_t\">Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/80\" class=\"nounderline abstract_t\">Lin Y, Stanworth S, Birchall J, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011; :CD005011.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/81\" class=\"nounderline abstract_t\">Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012; :CD005011.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/82\" class=\"nounderline abstract_t\">Brase J, Finger B, He J, et al. Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery. Ann Thorac Surg 2016; 102:35.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/83\" class=\"nounderline abstract_t\">Biss TT, Hanley JP. Use of recombinant factor VIIa (rFVIIa) in the management of intractable haemorrhage: a survey of current UK practice. Br J Haematol 2007; 138:126.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/84\" class=\"nounderline abstract_t\">Alfirevic A, Duncan A, You J, et al. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 2014; 98:618.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/85\" class=\"nounderline abstract_t\">Goodnough LT, Levy JH. The Judicious Use of Recombinant Factor VIIa. Semin Thromb Hemost 2016; 42:125.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/86\" class=\"nounderline abstract_t\">Harper PC, Smith MM, Brinkman NJ, et al. Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery. J Cardiothorac Vasc Anesth 2018; 32:151.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/87\" class=\"nounderline abstract_t\">Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev 2004; 18:105.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/88\" class=\"nounderline abstract_t\">Shander A, Javidroozi M, Naqvi S, et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion 2014; 54:2688.</a></li><li><a href=\"https://www.uptodate.com/contents/reducing-bleeding-and-minimizing-blood-transfusion-during-surgery/abstract/89\" class=\"nounderline abstract_t\">Shander A, Javidroozi M, Perelman S, et al. From bloodless surgery to patient blood management. Mt Sinai J Med 2012; 79:56.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 94347 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10487392\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H10487453\" id=\"outline-link-H10487453\">INTRODUCTION</a></li><li><a href=\"#H2373181178\" id=\"outline-link-H2373181178\">PREOPERATIVE STRATEGIES</a><ul><li><a href=\"#H2354604631\" id=\"outline-link-H2354604631\">Selective laboratory testing</a></li><li><a href=\"#H2290460988\" id=\"outline-link-H2290460988\">Management of medications affecting hemostasis</a></li><li><a href=\"#H1710529857\" id=\"outline-link-H1710529857\">Correction of anemia or thrombocytopenia</a><ul><li><a href=\"#H2062982004\" id=\"outline-link-H2062982004\">- Correction of anemia in selected patients</a></li><li><a href=\"#H3787518421\" id=\"outline-link-H3787518421\">- Treatment of thrombocytopenia for selected procedures</a></li></ul></li><li><a href=\"#H988137511\" id=\"outline-link-H988137511\">Treatment of vitamin K deficiency</a></li><li><a href=\"#H2401243333\" id=\"outline-link-H2401243333\">Management of anemia and hemostasis in renal insufficiency</a></li><li><a href=\"#H416906689\" id=\"outline-link-H416906689\">Management of hemostasis in hepatic insufficiency</a></li><li><a href=\"#H1535228623\" id=\"outline-link-H1535228623\">Management of specific hemostatic disorders</a><ul><li><a href=\"#H3602358630\" id=\"outline-link-H3602358630\">- Inherited conditions</a></li><li><a href=\"#H3272726424\" id=\"outline-link-H3272726424\">- Acquired disorders</a></li></ul></li><li><a href=\"#H1521510609\" id=\"outline-link-H1521510609\">Preoperative autologous blood donation</a></li></ul></li><li><a href=\"#H10487206\" id=\"outline-link-H10487206\">INTRAOPERATIVE STRATEGIES</a><ul><li><a href=\"#H10487212\" id=\"outline-link-H10487212\">Fluid management</a></li><li><a href=\"#H1848826462\" id=\"outline-link-H1848826462\">Temperature management</a></li><li><a href=\"#H111418635\" id=\"outline-link-H111418635\">Surgical blood conservation techniques</a><ul><li><a href=\"#H4716442\" id=\"outline-link-H4716442\">- Electrosurgery devices</a></li><li><a href=\"#H4064190888\" id=\"outline-link-H4064190888\">- Topical hemostatic agents and tissue adhesives</a></li><li><a href=\"#H1011872377\" id=\"outline-link-H1011872377\">- Acute normovolemic hemodilution</a></li><li><a href=\"#H3362458230\" id=\"outline-link-H3362458230\">- Intraoperative blood salvage</a></li></ul></li><li><a href=\"#H3894828099\" id=\"outline-link-H3894828099\">Selective use of procoagulant products</a><ul><li><a href=\"#H3095259769\" id=\"outline-link-H3095259769\">- Antifibrinolytics</a></li><li><a href=\"#H2826693653\" id=\"outline-link-H2826693653\">- Desmopressin (DDAVP)</a></li><li><a href=\"#H2978398940\" id=\"outline-link-H2978398940\">- Prothrombin complex concentrate (PCC)</a></li><li><a href=\"#H32315478\" id=\"outline-link-H32315478\">- Fibrinogen concentrate</a></li><li><a href=\"#H1302813894\" id=\"outline-link-H1302813894\">- Recombinant activated factor VII (rFVIIa)</a></li></ul></li></ul></li><li><a href=\"#H3840640628\" id=\"outline-link-H3840640628\">REFUSAL OR LIMITED AVAILABILITY OF BLOOD</a></li><li><a href=\"#H10487392\" id=\"outline-link-H10487392\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ANEST/94347|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=SURG/58281\" class=\"graphic graphic_figure\">- Normal thromboelastography and parameters</a></li><li><a href=\"image.htm?imageKey=SURG/51767\" class=\"graphic graphic_figure\">- Primary hyperfibrinolysis</a></li><li><a href=\"image.htm?imageKey=SURG/70388\" class=\"graphic graphic_figure\">- Secondary hyperfibrinolysis</a></li><li><a href=\"image.htm?imageKey=SURG/58977\" class=\"graphic graphic_figure\">- Hypercoagulability</a></li></ul></li><li><div id=\"ANEST/94347|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/79151\" class=\"graphic graphic_table\">- Options warfarin-associated bleeding</a></li><li><a href=\"image.htm?imageKey=EM/89478\" class=\"graphic graphic_table\">- Emergent reversal of anticoagulation from warfarin in adults</a></li><li><a href=\"image.htm?imageKey=HEME/96230\" class=\"graphic graphic_table\">- Reversal strategies DOAC bleeding</a></li><li><a href=\"image.htm?imageKey=HEME/112299\" class=\"graphic graphic_table\">- DOAC reversal agents for life-threatening bleeding</a></li><li><a href=\"image.htm?imageKey=HEME/87698\" class=\"graphic graphic_table\">- ITP treatment response times</a></li><li><a href=\"image.htm?imageKey=HEME/110532\" class=\"graphic graphic_table\">- DDAVP use for hemostasis</a></li><li><a href=\"image.htm?imageKey=HEME/94210\" class=\"graphic graphic_table\">- US PCC products</a></li><li><a href=\"image.htm?imageKey=HEME/67244\" class=\"graphic graphic_table\">- Religious position medical therapy</a></li><li><a href=\"image.htm?imageKey=HEME/106229\" class=\"graphic graphic_table\">- Checklist for blood product refusal</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-inhibitors-of-coagulation\" class=\"medical medical_review\">Acquired inhibitors of coagulation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-von-willebrand-syndrome\" class=\"medical medical_review\">Acquired von Willebrand syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-elective-spine-surgery-in-adults\" class=\"medical medical_review\">Anesthesia for elective spine surgery in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-unexplained-thrombocytopenia\" class=\"medical medical_review\">Approach to the adult with unexplained thrombocytopenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiopulmonary-bypass-preparations-and-initiation\" class=\"medical medical_review\">Cardiopulmonary bypass: Preparations and initiation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-and-laboratory-aspects-of-platelet-transfusion-therapy\" class=\"medical medical_review\">Clinical and laboratory aspects of platelet transfusion therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults\" class=\"medical medical_review\">Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-use-of-cryoprecipitate\" class=\"medical medical_review\">Clinical use of Cryoprecipitate</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coagulopathy-associated-with-trauma\" class=\"medical medical_review\">Coagulopathy associated with trauma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-and-acquired-disorders-of-platelet-function\" class=\"medical medical_review\">Congenital and acquired disorders of platelet function</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disorders-of-fibrinogen\" class=\"medical medical_review\">Disorders of fibrinogen</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fondaparinux-dosing-and-adverse-effects\" class=\"medical medical_review\">Fondaparinux: Dosing and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemostatic-abnormalities-in-patients-with-liver-disease\" class=\"medical medical_review\">Hemostatic abnormalities in patients with liver disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=heparin-and-lmw-heparin-dosing-and-adverse-effects\" class=\"medical medical_review\">Heparin and LMW heparin: Dosing and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-thrombocytopenia-itp-in-adults-initial-treatment-and-prognosis\" class=\"medical medical_review\">Immune thrombocytopenia (ITP) in adults: Initial treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult\" class=\"medical medical_review\">Indications and hemoglobin thresholds for red blood cell transfusion in the adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-management-of-moderate-to-severe-hemorrhage-in-the-adult-trauma-patient\" class=\"medical medical_review\">Initial management of moderate to severe hemorrhage in the adult trauma patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraoperative-fluid-management\" class=\"medical medical_review\">Intraoperative fluid management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraoperative-transfusion-of-blood-products-in-adults\" class=\"medical medical_review\">Intraoperative transfusion of blood products in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants\" class=\"medical medical_review\">Management of bleeding in patients receiving direct oral anticoagulants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr\" class=\"medical medical_review\">Management of warfarin-associated bleeding or supratherapeutic INR</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=massive-blood-transfusion\" class=\"medical medical_review\">Massive blood transfusion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-management-of-the-dialysis-patient-undergoing-surgery\" class=\"medical medical_review\">Medical management of the dialysis patient undergoing surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-electrosurgery\" class=\"medical medical_review\">Overview of electrosurgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-topical-hemostatic-agents-and-tissues-adhesives\" class=\"medical medical_review\">Overview of topical hemostatic agents and tissues adhesives</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-vitamin-k\" class=\"medical medical_review\">Overview of vitamin K</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-anaphylaxis-clinical-manifestations-etiology-and-management\" class=\"medical medical_review\">Perioperative anaphylaxis: Clinical manifestations, etiology, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants\" class=\"medical medical_review\">Perioperative management of patients receiving anticoagulants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-medication-management\" class=\"medical medical_review\">Perioperative medication management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=plasma-derivatives-and-recombinant-dna-produced-coagulation-factors\" class=\"medical medical_review\">Plasma derivatives and recombinant DNA-produced coagulation factors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=platelet-dysfunction-in-uremia\" class=\"medical medical_review\">Platelet dysfunction in uremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postpartum-hemorrhage-medical-and-minimally-invasive-management\" class=\"medical medical_review\">Postpartum hemorrhage: Medical and minimally invasive management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preoperative-assessment-of-hemostasis\" class=\"medical medical_review\">Preoperative assessment of hemostasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preoperative-medical-evaluation-of-the-adult-healthy-patient\" class=\"medical medical_review\">Preoperative medical evaluation of the adult healthy patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rare-inherited-coagulation-disorders\" class=\"medical medical_review\">Rare inherited coagulation disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects\" class=\"medical medical_review\">Recombinant factor VIIa: Clinical uses, dosing, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=red-blood-cell-transfusion-in-sickle-cell-disease\" class=\"medical medical_review\">Red blood cell transfusion in sickle cell disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reversal-of-anticoagulation-in-warfarin-associated-intracerebral-hemorrhage\" class=\"medical medical_review\">Reversal of anticoagulation in warfarin-associated intracerebral hemorrhage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer\" class=\"medical medical_review\">Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgical-blood-conservation-blood-salvage\" class=\"medical medical_review\">Surgical blood conservation: Blood salvage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgical-blood-conservation-intraoperative-hemodilution\" class=\"medical medical_review\">Surgical blood conservation: Intraoperative hemodilution</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgical-blood-conservation-preoperative-autologous-blood-donation\" class=\"medical medical_review\">Surgical blood conservation: Preoperative autologous blood donation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-approach-to-the-patient-who-refuses-blood-transfusion\" class=\"medical medical_review\">The approach to the patient who refuses blood transfusion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=total-hip-arthroplasty\" class=\"medical medical_review\">Total hip arthroplasty</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-anemia-in-hemodialysis-patients\" class=\"medical medical_review\">Treatment of anemia in hemodialysis patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-anemia-in-nondialysis-chronic-kidney-disease\" class=\"medical medical_review\">Treatment of anemia in nondialysis chronic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-bleeding-and-perioperative-management-in-hemophilia-a-and-b\" class=\"medical medical_review\">Treatment of bleeding and perioperative management in hemophilia A and B</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">Treatment of iron deficiency anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-von-willebrand-disease\" class=\"medical medical_review\">Treatment of von Willebrand disease</a></li></ul></div></div>","javascript":null}